Regentis Biomaterials Ltd. RGNT Archives

ThursdayOct 08, 2026 2:30 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee cartilage treatment from symptom management toward early structural repair. Unlike microfracture, which can produce less-durable fibrocartilage, GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage, while avoiding cell harvesting and a second surgery. In a Phase II study, the company reported roughly 100% greater KOOS improvement versus microfracture at 24 months, along with a mean MOCART score of 88.8/100 indicating strong structural repair. With CE Mark approval in Europe, a pivotal U.S. trial targeting completion around year-end 2026, and longer-term development programs…

ThursdayOct 01, 2026 12:00 pm

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

One of the challenges in cartilage repair is that some procedures can provide meaningful short-term pain relief without restoring durable, functional cartilage capable of withstanding the demands of an active joint. Regentis Biomaterials is taking a regenerative approach with GelrinC, a cell-free, off-the-shelf hydrogel designed to temporarily fill cartilage defects while guiding the healthy surrounding tissue to regenerate new, natural and highest hyalin quality cartilage. Recent long-term MRI and peer-reviewed clinical data have provided additional evidence supporting the quality and durability of knee cartilage regenerated with GelrinC, as the company advances its U.S. pivotal trial and commercialization efforts in Europe.…

MondaySep 28, 2026 2:00 pm

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

Orthopedic practice is moving away from a model that manages knee pain until the joint fails, to early structural intervention - a shift that raises the bar for what a cartilage repair product has to deliver. Regentis' GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage, with Phase II data showing approximately 100% greater KOOS improvement than microfracture at two years. With CE Mark approval in Europe, pivotal U.S. trial enrollment targeted for completion by approximately year end 2026, and platform work extending toward moderate osteoarthritis, the company is…

ThursdaySep 17, 2026 2:32 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Into Pivotal Stage of Development

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, an off-the-shelf hydrogel implant designed to support the body’s natural regeneration of damaged knee cartilage. Delivered as a liquid and cured in place with UV light, GelrinC forms a temporary scaffold that gradually degrades over roughly six to nine months, creating an environment intended to support the development of new cartilage without requiring cell harvesting or laboratory expansion. The company cites encouraging Phase 2 data from 56 patients, including improvements in pain and function through four years of follow-up, and says imaging has…

FridaySep 11, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss. Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment. Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval. A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly,…

WednesdaySep 02, 2026 3:39 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care

Regentis Biomaterials (NYSE American: RGNT) is advancing a regenerative approach to cartilage repair with GelrinC, a cell-free, off-the-shelf hydrogel implant designed to create a temporary environment that supports the body’s natural ability to regenerate damaged knee cartilage. Unlike conventional implants that primarily replace or reinforce damaged tissue, GelrinC is injected into a cartilage lesion and cured in place with ultraviolet light before gradually degrading as new tissue develops. The company reports encouraging clinical results, including greater pain improvement versus microfracture at two years and MRI evidence of cartilage regeneration. GelrinC already has CE Mark approval in Europe, where Regentis is preparing for…

ThursdayAug 27, 2026 3:07 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40 enrolled patients closely match the historical control group in baseline characteristics. In Europe, where GelrinC already has CE Mark approval, Regentis is preparing for broader commercialization through surgeon training, an expanding network of Centers of Excellence…

ThursdayAug 27, 2026 12:45 pm

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? Researchers are pursuing that question through…

TuesdayAug 18, 2026 1:50 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This followed a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents. Regentis’ proprietary manufacturing process increases yield fivefold, simplifies production and is built to support commercial-scale manufacturing—important advantages for an off-the-shelf cartilage-repair product designed to avoid the complexity and cost of cell-based procedures. The milestone comes as the company…

FridayAug 14, 2026 1:28 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article highlighting the potential of its GelrinC cell-free hydrogel implant to address longstanding challenges in focal knee injuries through an off-the-shelf treatment designed to simplify surgical workflows, support faster recovery and promote durable tissue regeneration. The company recently received European regulatory approval for a next-generation, solvent-free manufacturing process that increases production yield by approximately 400%, supporting greater scalability and lower production costs. Regentis is also advancing surgeon training and European commercialization while progressing its pivotal U.S. Phase III SAGE trial, which is more than 50% enrolled. GelrinC’s combination of procedural simplicity, clinical…

Site Search

Company Search

Tag: Regentis Biomaterials Ltd. RGNT